combining tirzepatide and retatrutide Semaglutide vs vs retatrutide: the complete three-way comparison Retatrutide vs Tirzepatide vs Semaglutide

The combined effect on both pressure measurements translates to meaningful reductions in cardiovascular risk over time

01 mechanism of action Retatrutide (LY3437943) is an experimental triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors a previously unique combination in peptide research

Patients should always discuss the risks and benefits with their healthcare provider

Their activation by ligands such as PYY(1-36) inhibits cAMP and elevates Ca + , jointly regulating intestinal smooth muscle tone and secretion, affecting gastric emptying and colonic motility (63)

Key findings from SURMOUNT-5 at 72 weeks: Tirzepatide produced a mean body weight reduction of 20.2% compared to 13.7% with semaglutide

Efficacy and safety of glucagonlike peptide1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials